Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 397 (ZNF397) is a human transcription factor containing a N-terminal SCAN domain and multiple C2H2-type zinc finger repeats, which allow it to bind DNA and participate in transcriptional regulation[2][3]. ZNF397 functions as a coactivator of the androgen receptor, playing an essential role in maintaining androgen receptor-driven luminal lineage programs in prostate tissue[1]. Loss of ZNF397 induces lineage plasticity in prostate cancer cells via a switch to TET2-dependent epigenetic programs, promoting resistance to androgen receptor-targeted therapies[1]. Although not a receptor, enzyme, or traditional therapeutic target, ZNF397 is a transcriptional regulator with emerging roles in cancer progression and therapy resistance[1][2][3]. No drugs are currently known to directly target ZNF397, but TET2 inhibitors can reverse resistance phenotypes associated with its loss in preclinical models[1].
Modulation of epigenetic state via regulation of androgen receptor-driven transcriptional programs and interaction with TET2-dependent pathways
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 397 (ZNF397).